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Young female athletes experience a higher incidence of ligament injuries than their male counterparts, females
experience a higher incidence of joint hypermobility syndrome (a risk factor for osteoarthritis development), and
post-menopausal females experience a higher prevalence of osteoarthritis than age-matched males. These
observations indicate that fluctuating sex hormone levels in young females and loss of ovarian sex hormone
production due to menopause likely contribute to observed sex differences in knee joint function and risk for loss
of function. In studies of osteoarthritis, however, there is a general lack of appreciation for the heterogeneity of
hormonal control in both women and men. Progress in this field is limited by the relatively few preclinical
osteoarthritis models, and that most of the work with established models uses only male animals. To elucidate sex
differences in osteoarthritis, it is important to examine sex hormone mechanisms in cells from knee tissues and the
sexual dimorphism in the role of inflammation at the cell, tissue, and organ levels. There is a need to determine if
the risk for loss of knee function and integrity in females is restricted to only the knee or if sex-specific changes in
other tissues play a role. This paper discusses these gaps in knowledge and suggests remedies.
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Introduction
The knee comprises a number of tissues (bones, muscle,
cartilage, menisci, ligaments, tendons, synovium, and
capsule) that function as an organ system during rapid
growth, adult life, and aging. As with other organ sys-
tems, the integrity and function of the knee is controlled
locally and systemically by different hormones, including
sex hormones (estrogens, androgens, and progesterone)
and their metabolites. Degenerative changes in the knee
result in osteoarthritis (OA) in women and men, but
there are sex-dependent differences in the incidence and
severity of the disease that vary with hormonal status.* Correspondence: bboyan@vcu.edu
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reproduction in any medium, provided the orThe focus of preclinical OA studies has been on in vitro
and in vivo male models, which neglects both the sexual
dimorphic component of the disease and the potential
effects of sex hormones on the incidence and progres-
sion of knee OA, as well as on the regenerative potential
of affected cartilage. Recent studies examining the role
of migratory chondrogenic progenitor cells in the repair
of OA cartilage show that there are sex differences in
the response of these cells to estrogen and testosterone
[1]. Premenopausal levels of estrogen stimulate chondro-
genesis in female progenitor cells, whereas testosterone
stimulates chondrogenic differentiation of male progeni-
tor cells. The purpose of this review is to summarize
current knowledge on the role of sex hormones in
modulating knee homeostasis and how changes in the
sex hormone milieu during development and aging con-
tribute to the incidence, severity, and progression of
knee OA.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Sex hormones are a group of steroids derived from chol-
esterol that share a number of characteristics. Estrogens,
androgens, and progesterones possess a cholesterol
backbone (Figure 1) that make them lipid soluble. The
synthesis of sex steroids is both sex- and tissue-
dependent. Sex steroids are produced primarily in the
sex glands and function systemically as part of the endo-
crine system. The circulating levels of these hormones
reflect sex differences in both gonadal secretion and
peripheral metabolism, both of which are sensitive to
the availability of precursors and cyclic changes in regu-
latory factors. Circulating levels also change with physio-
logical status. Circulating estrogen is high around the
time of birth in both males and females and lower in
males than females during early growth and develop-
ment. At puberty, testosterone levels increase in males,
whereas estrogen and progesterone increase in females.
At menopause, estrogen levels decrease in women to
levels that are lower than circulating levels in men.
Sex steroids are produced in other tissues besides the
gonads, including the connective tissues of the knee,Figure 1 Synthesis of sex steroids (http://en.wikipedia.org/wiki/File:St
enzymatic pathways for synthesis of different biologically active steroid me
are regulated in different tissues by the expression of specific enzymes tha
endoplasmic reticulum. Some tissues (e.g., adrenal glands, gonadal tissues)
metabolites, whereas others can be made locally in tissues such as articulawhere they serve autocrine/paracrine functions. There is
also sexual dimorphism in the extra-glandular metabol-
ism of sex steroids. In growth plate chondrocytes from
males, for example, testosterone is predominantly meta-
bolized by 5α-reductase, resulting in the production of
DHT [2]. In growth plate cartilage cells from females,
testosterone is predominantly metabolized by aromatase,
resulting in the production of estrogens. Thus, sex-
specificity may be conferred not only by gonadal hormone
secretion, but also by steroidogenic enzyme activity in
knee tissues.
Mechanism of action
Sex steroids bind to cytosolic receptors, which then
dimerize and translocate to the nucleus to modulate
gene transcription [3]. Steroid hormones also act at the
level of the cell membrane by stimulating signal trans-
duction pathways traditionally associated with G-protein
coupled receptors [4,5]. Cells in knee articular cartilage,
as well as bone and muscle, in both males and females
express receptors for estrogens, androgens, progester-
one, and their metabolites [1], suggesting that both sexeseroidogenesis.svg#file). The schematic indicates the various
tabolites of cholesterol as the starting molecule. The various pathways
t catalyze the metabolic conversions in mitochondria and smooth
are the primary source of some of the biologically active steroid
r cartilage when appropriately stimulated.
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marily with one sex. The numbers of receptors, their
affinity for a hormone or hormone metabolite, or the
presence and function of components of a particular sig-
naling pathway may vary in a sex-specific manner [6-8].
In addition, individual tissues in the knee may be regu-
lated by sex hormones in a differential manner that may
influence the function of the knee as an organ system.Contribution of sex steroids to knee OA
The research summarized in the next section indicates
that differences in the regulation of individual tissues of
the knee by sex hormones may influence the incidence
and severity of OA. There are a number of potential
mechanisms that may mediate this effect (Table 1). The
goal of this paper is to present a synopsis of the current
state of knowledge of sex hormone regulation of knee
tissues and to identify gaps in knowledge.
Mechanisms of sex hormone function
Sex hormones act via traditional steroid hormone recep-
tor-mediated mechanisms and via membrane-associated
rapid signal transduction pathways. How these receptor-
dependent mechanisms impact knee homeostasis is dis-
cussed briefly.
Estrogen Receptors (ER)
ERα and ERβ are the products of different genes. Both
receptor forms are found in estrogen responsive cells, but
often at differing levels [9]. ERα is present in two isoforms,
ERα66 and a truncated form, ERα46. In addition, a third
form of ERα has been identified, ERα36, which is encoded
by a different gene. ER-estrogen complexes can interact
with DNA directly via estrogen-response elements (EREs)
after dimerization or via complexes with other nuclear
proteins to interact with other DNA sites such as AP-1
[10]. The concept of ligand-independent and ligand-
dependent actions of ERs is further substantiated by the
presence of ER variants in bones, termed estrogen-related
receptors (ERR), which lack the ligand-binding domain in
their structure [11,12]. Thus, the presence of hormones isTable 1 Complexities in hormonal regulation of knee
tissues contribute to sex-differences in severity and
incidence of knee OA
● Changes in systemic levels of sex steroids.
● Changes in local production of hormones or their metabolites.
● Presence of hormone receptors, their affinity for ligand, or components of
their signaling pathway.
● Distribution of hormone-responsive cells in individual tissues of the knee.
● Physiological status, including age and the presence of disease or tissue
injury.not required for ERs and their respective ligands to influ-
ence tissues such as those of the knee.
ERα and ERβ have also been found associated with the
plasma membranes of estrogen responsive cells [9,13-
15], where they play a role in rapid responses to the hor-
mone and membrane-associated signaling pathways [16].
In human articular chondrocytes, membrane-mediated
signaling increases cell proliferation and cartilage matrix
production [17,18]. This effect of estrogen is observed
primarily in cells from female donors, but the reasons
for this sex-specificity are not well understood. In
growth-plate chondrocytes, there are differences in the
number of total receptors (females > males) [15,18] and
there are differences in ERα36 that may impact its
mechanism of action (ElBaradie, Schwartz, Boyan et al.
unpublished data), but it is not known if similar differ-
ences exist in articular chondrocytes. The actual scope of
influence of the plasma membrane-associated receptors in
articular cartilage is only now emerging, but the field is
progressing rapidly [19] and it may prove important in
designing therapeutic approaches for treating knee OA.
Androgen receptors
The androgen receptor (AR) is also a member of the nu-
clear hormone receptor family. There are traditional nu-
clear ARs and plasma membrane-associated ARs [20,21],
similar to the ERs. Furthermore, some AR variants lack-
ing a ligand-binding domain have been detected in both
normal and cancerous tissues [22-24]. As both males
and females produce testosterone and its metabolites, it
is likely that the AR also influences some functions in
females [25]. Recent studies suggest, however, that the
cellular responses may be sex-specific. Female growth
plate chondrocytes convert testosterone to estrogen,
whereas male growth plate chondrocytes convert it to
dihydrotestosterone (DHT) [2], and only male cells ex-
hibit rapid membrane-associated responses to DHT [26].
The sex of the cell, therefore, may determine the out-
come of ligand receptor binding more than simply the
presence of the receptors in the cells.
Progesterone receptors
Traditional progesterone receptors (PR) exist as two nat-
ural genetic variants (PR-A and PR-B). Both variants can
be expressed in the same cell, but the ratio of PR-A/PR-
B can vary between cells [27], similar to that for ERα/
ERβ [28]. In addition, membrane-associated forms of PR
have been detected on various cells [29]. The widespread
occurrence of PRs and conjugated ligands indicates they
may have a more general influence on cell metabolism
and function in connective tissues, such as those of the
knee. This conclusion has been implicated from the
study of menstrual cycle-associated alterations in knee
joint laxity in subsets of young females [30].
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Much information about the function of sex hormone
receptors has been gleaned from either naturally occur-
ring mutations in preclinical models, or from induced
deficiencies via generation of knockout (KO) mice [31].
Preliminary studies using the double ERα/ERβ KO
mouse have not revealed histological differences in knee
tissues (Hart et al., unpublished). There do not appear to
be alterations to collagen fibril diameters and density in
the ligaments of these mice, suggesting that the deficien-
cies do not exert a detectable impact on collagen assem-
bly, but the biomechanical properties of the ligaments
have not been assessed. These mice do possess ERα36,
however, raising the possibility that this ER-variant is
important in defining sex differences in response to es-
trogen. How this impacts human knee OA is unknown.
Sex hormone receptors and the knee
As detected by either immunolocalization or assessment
of mRNA levels, expression of sex hormone receptors
has been reported in nearly all tissues of the knee. Stud-
ies comparing chondrocytes in the growth plates of mice
and rats and on articular chondrocytes from rats and
human donors indicate that ERs and ARs are present in
cells from both sexes [1,18,32]. Moreover, they exhibit
comparable binding affinities for their ligands. However,
the numbers of ER receptors are reduced in males rela-
tive to females [18]; it is not known if a comparable dif-
ference in ARs also exists. Unfortunately, quantification
studies have usually not been done at a functional (e.g.,
protein level) level for most tissue-based studies. Thus,
mRNA detection does not guarantee translation and
immunolocalization does not necessarily detect intact
receptors. One additional limitation is the lack of avail-
ability of an appropriate spectrum of reagents for some
species of receptors.
Despite these limitations in our understanding of the
regulation of sex hormone receptors in many tissues of
the knee, it appears that receptor levels are dynamic and
not static. For example, mRNA levels for ERs in tissues of
the rabbit knee, as detected by RT-PCR, can be signifi-
cantly influenced (significant elevations or depressions) by
pregnancy, ligament injury, ovariohysterectomy, develop-
ment of osteoarthritis following ACL transection, and
during development of antigen-induced arthritis [33]. Fur-
thermore, ER and PR mRNA levels appear to be regulated
independently, indicating that separate elements influence
expression levels. Although human tissues have not been
assessed as extensively as those of preclinical models, the
associations likely extend across species.
Although it is difficult to examine hormone receptors
in intact tissues of the knee, due mainly to the paucity of
cells in these matrix-rich environments, such studies are
possible by using cells derived from the tissues. Thesetypes of studies have focused mainly on cells from bone
(osteoclasts and osteoblasts), articular cartilage (chon-
drocytes) [17], skeletal muscle, synovial cells (type A and
type B), tendon (tenocytes, paratenon cells), ligaments
(ligament proper and epiligament cells) [34], and to a
lesser extent cells from menisci and joint capsule. There
are virtually no direct comparisons between cells of mul-
tiple tissues and only limited studies between cells from
females and males. It is likely that differences in receptor
levels exist, as noted above.
Sources of ligands for sex hormone receptors
Ligands for sex hormones can be generated by specific
organs (endocrine system) and transported by the circu-
lation to reach various target tissues, produced locally by
cells such as macrophages and synthesized locally by
metabolic alteration through expression of specific
enzymes that are unique to various tissues and cells [35].
As many of the natural ligands are modified from com-
mon precursors via interactive pathways, the availability
of ligands in males and females depends on the expres-
sion of specific enzymes. Molecules that can interact
with sex hormone receptors can also be acquired via the
environment and diet (e.g., phytoestrogens) [36]. Select-
ive estrogen-receptor modifiers (SERMs) are molecules
that can differentially influence ERα vs ERβ [37]. For ex-
ample, tamoxifen, a drug widely used to treat breast can-
cer [38], can have a positive effect on ERα activity in
breast tissue, but it increases cancer risk via association
with ERβ in the ovaries [39]. How such SERMs influence
cells in knee tissues is largely unknown.
Ligand availability is critical; premenopausal women
have higher levels of circulating estrogens than men, and
men have higher circulating levels of testosterone than
women [40]. Moreover, there are sex differences in local
concentrations of these hormones among those tissues
that are able to synthesize sex steroids locally. Local
production of ligands that can interact with sex hor-
mone receptors with varying affinity and outcomes can
be achieved in tissues such as bone and cartilage.
Growth plate chondrocytes produce estrogen and DHT
locally and at levels as high as 10-8 M [2,41], four orders
of magnitude higher than in the blood. Similarly, articu-
lar chondrocytes also exhibit the ability to metabolize
testosterone to estrogen and DHT [42,43]. The observa-
tion that cartilage cells respond to these concentra-
tions via membrane-associated signaling pathways
suggests that sex differences in these cells are likely
due to local production and signaling, although it
should be noted that sex differences have also been
observed using concentrations of sex hormones at levels
comparable to those found in blood [1]. How such differ-
ences could contribute to risk for loss of knee function
remains to be determined.
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connective tissues of the knee have tended to assume
the effects are direct. For example, investigators have ei-
ther added specific agonist or antagonist ligands to
in vitro cell populations and observed the outcomes on
cell metabolism or explant behavior, or replaced the endo-
crine products in vivo that are lost due to surgical castra-
tion (removal of ovaries/uterus, testicles). In addition,
many of these studies use concentrations of the specific
ligands that exceed circulating physiologic levels.
A second issue regarding the influence of sex hormone
effects on the connective tissues of the knee is that all
tissues of the knee, with the exception of articular cartil-
age, are innervated and vascularized. Therefore, the influ-
ence of sex hormones from the endocrine system, which
are transported by the microvasculature to the target cells
within the tissues, could influence the knee tissues via the
endothelial cells of the vasculature. Alternatively, the
modulation could be achieved either directly or indirectly
by neuropeptides via the neuroendocrine system. The ex-
ception to these possible indirect mechanisms is articular
cartilage (avascular and aneural), where hormones pro-
duced by the endocrine system must diffuse into the tissue
or be produced locally.
The balance between sex hormone receptors and their
ligands
Although both males and females express estrogen, pro-
gesterone, and androgen receptors and make various
ligands for those receptors, they do so at different levels
and via distinct regulatory pathways. The levels for spe-
cific ligands change across the lifespan and are matched
by changes in receptors, as well as intracellular proteins
that can function as co-activators/co-repressors [44].
These adjustments result in function being related to the
balance between the involved elements, and menopause
corresponds to a change in the balance between estro-
gen, progesterone, and testosterone-related ligands pro-
duced systemically and locally rather than just a loss of
specific endocrine components. However, the impact of
systemic loss of endocrine contributions (e.g., meno-
pause) to this balance likely varies across tissues due to
differences in the expression levels of hormone receptors
and the potential to produce ligands locally.
Studies in preclinical rabbit models have indicated that
levels of estrogen receptors in connective tissues of the
knee can be influenced by injuries to the knee (ACL
transection, MCL transection) and hence, their levels are
dynamic and not static in the cells of these tissues. Thus,
ER levels in tissues of the knee are differentially influ-
enced by systemic and locally produced ligands. There-
fore, in females where hormone levels can fluctuate over
the menstrual cycle, during pregnancy, and following
menopause, cells in connective tissues of the knee wouldlikely experience a more varying hormonal environment
than age-matched males.
Sex differences in hormonal regulation of knee tissues and
function
The discussion in the preceding sections focused on the
biochemistry and cell biology of sex steroids and their
receptors. This section examines how such hormone/
hormone receptor systems impact specific tissues of the
knee, and how such an influence may contribute to sex
differences in the development of OA.
Anterior cruciate ligament
The incidence of knee injuries, particularly those involv-
ing the anterior cruciate ligament (ACL), is more com-
mon in female athletes than males for a number of
sports [45-49]. The prevalence of ACL injuries experi-
enced by females in such sports as soccer, basketball,
and handball is 5- to 10-times greater than in males, and
most are non-contact injuries. The peak age of increased
risk in females is 16–20 years, which is a time of growth
and development underlying puberty. It remains unclear
how changes in systemic sex hormones may influence
susceptibility to ACL injury.
Cyclic sex hormone-dependent joint laxity has been
implicated in the etiology of ACL injury in young women,
although this is not a uniform finding [30,49,50]. The
mixed findings may reflect differences in how the studies
were conducted or differences in the populations exam-
ined. The latter hypothesis is supported by the observation
that menstrual phase-associated changes in knee function
were apparent in some females and not others, even
though changes in estrogen and progesterone were com-
parable [31,51,52]. When changes in knee function were
observed, they usually involved knee joint laxity and
muscle function. Because joint laxity is likely more critical
when the extra-articular ligaments and the capsule experi-
ence low loads, modulation of joint laxity during the
menstrual cycle may influence positioning and function of
the knee during high-risk maneuvers [53,54].
There is an urgent need to identify the mechanisms
and individuals at risk for ACL injury because approxi-
mately 50% of those who experience such an injury de-
velop overt knee OA irrespective of whether or not the
ACL is surgically reconstructed using conventional
orthopedic procedures [55]. The reason for the prevalent
progression to knee OA after ACL injury is not known.
It is clear that ACL rupture can lead to altered knee sta-
bility, but it is not known if the injury is exacerbated by
previous menstrual cycle-associated alterations in joint
laxity, or if the downstream effects of the injury itself
dominate the eventual outcome. Potential contributing
factors include collateral tissue damage (e.g., meniscal
injury) at the time of the ACL injury, injury-associated
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cycle-associated exacerbations of injury-induced changes
to knee function.
Ligament injury appears to play a role in the sex-
dependent development of knee OA, but it is less clear
whether there are sex differences in OA development
early after a knee injury (10–15 years) [56-58]. Sex differ-
ences in outcomes after ACL injury and reconstruction
have been reported [59], suggesting that there may be sex
differences in outcomes following knee injury as well.
However, there is no consensus on this possibility [60].
Joint hypermobility syndrome and knee OA
The prevalence of joint hypermobility syndrome (JHS),
formerly called benign JHS, is associated with a general-
ized condition where individuals have lax joints (e.g.,
“double jointed”) and is ~5 times more common in
females than in males. JHS has been associated with
mutations in some matrix molecules [61-63], but non-
syndromic forms have also been identified. There are
also population differences in the incidence of JHS
[49,61], further complicating the identification of sex dif-
ferences in its prevalence. Females with the syndrome
exhibit a low-grade synovitis, possibly related to accu-
mulated micro-injury of the knee due to load-related
damage [64]. Because the control of inflammatory pro-
cesses in females can differ from those in males, the sig-
nificance of synovitis in the knees of females with joint
hypermobility syndrome remains to be clarified.
Genetics presumably contribute to the development of
JHS, but non-genomic or epigenetic variables must also
be involved because concordance was less than 100% in
identical twins [65]. It is not known whether females
with JHS experience modulation of joint laxity during
the menstrual cycle or pregnancy. Interestingly, an in-
verse association between joint hypermobility and knee
osteoarthritis has been reported [66]. Although this find-
ing may appear counterintuitive, the study involvedFigure 2 Variable response of male human articular chondrocytes to
(<30 years) with no evidence of OA. Confluent cultures of second-passage
and proteoglycan production was measured as a function of 35S-sulfate inc
extracellular matrix. Data are means ± SEM, N = 6 independent cultures pe
exhibited no response to the hormone in two different sets of experiment
hormone. Data are provided courtesy of Ramsey Kinney, MD, PhD, Departm
Atlanta, GA.multiple cohorts and suggests that it is necessary to re-
assess concepts related to inflammation and joint posi-
tioning with knee OA development.Direct effects of sex hormones on articular cartilage
Sex steroids appear to have complex effects on articular
cartilage via direct actions on chondrocytes and contrib-
ute to OA-associated changes, but many details remain
to be determined [67]. Human articular chondrocytes ex-
press estrogen receptors ERα and ERβ [68,69], indicating
that they are estrogen-responsive cells. In organ cultures
from mature rat articular cartilage, estrogens reduce chon-
drocyte proliferation and increase chondrocyte hyper-
trophy based on thinning of the cartilage and production
of type X collagen [70]. In contrast, 17β-estradiol results
in proliferation of chondrocytes from adult humans and
stimulates production of type II collagen and aggrecan
[68]. Furthermore, premenopausal concentrations of 17β-
estradiol prevent telomere shortening in articular chon-
drocytes whereas post-menopausal concentrations do not
[71], supporting the hypothesis that estrogens protect
against OA via direct actions on chondrocytes. Moreover,
17β-estradiol reduces expression of matrix metalloprotei-
nases associated with cartilage matrix degradation in OA
[72]. Although cells from male and female donors have
ERα and ERβ, female cells are more responsive to 17β-
estradiol than male cells [17,69]. Male cells can respond to
high concentrations of the hormone, but this is not a con-
sistent finding. When human articular chondrocytes were
examined for rapid activation of protein kinase C in re-
sponse to 17β-estradiol, no increase in enzyme activity
was observed in male cells, whereas all female chondro-
cytes responded. In contrast, synthesis of extracellular
matrix proteoglycan, which depends on traditional nuclear
receptor binding, was variable with 17β-estradiol having a
stimulatory effect on cells from one of three male donors
(Figure 2). This suggests that the sex-specific responses to17β-estradiol. Chondrocytes were isolated from three male donors
cultures were treated with 10-8 to 10-10 M 17β-estradiol for 24 hours
orporation into sulfated glycosaminoglycans, a hallmark of cartilage
r variable. *p < 0.05, treatment v. control. Cells from two of the donors
s, whereas cells from one of the donors were responsive to the
ent of Orthopaedics, Emory University School of Medicine,
Table 2 Research gaps in our understanding of sex
differences in OA
1. Lack of good epidemiologic information on heterogeneity in both
the female and male populations with respect to hormonal status v.
incidence and severity of OA.
2. Need for basic science studies on the etiology of OA in males v.
females.
3. Lack of valid preclinical in vitro and in vivo models of osteoarthritis.
4. Absence of studies specifically examining sex hormone mechanisms
in cells from knee tissues.
5. Uncertainty about the role of inflammation at the cell, tissue, and
organ levels.
6. Need to determine if the risk for loss of knee function and integrity
in females is restricted to only the knee or if sex-specific changes in
other tissues play a role.
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forms of the estrogen receptor.
Less is known about the direct effects of testosterone
on articular chondrocytes, but cells from both male and
female donors express receptors for testosterone and
DHT [72], indicating that these cells are sensitive to
regulation by androgens. In addition, articular chondro-
cytes possess the ability to synthesize estrogens and
androgens [73], further supporting the hypothesis that
sex steroids act directly on these cells. Several studies
found that androgens protect against cartilage degrad-
ation in rheumatoid arthritis, suggesting they play a
similar role in OA, but it is not known if this is a direct
effect of testosterone or DHT or if it is due to estrogen
produced locally via aromatase action.
The discrepancies among different studies are likely
due to a variety of issues: whether male or female cells
and tissues were used, the age of the donors, the species
of donor, the concentration and length of exposure to
the hormone, the maturation state of the cells in culture,
whether cells came from healthy or osteoarthritic tissue,
and the site within the articular cartilage from which the
cells were isolated. The lack of consistency among stud-
ies has made it difficult to assess the role of sex steroids
in the etiology of OA.
Menopause-associated risk for development of knee OA
Prior to menopause, the incidence of idiopathic knee
OA is similar in women and men. After menopause,
however, the prevalence is much greater in females than
age-matched males [74,75]. These observations indicate
that withdrawal of ovarian hormones increases risk for
the development and progression of overt knee OA in
women. However, not all postmenopausal women de-
velop knee OA and it is not clear what distinguishes
those who do from those who do not. To address this
gap in knowledge, some studies have begun to investi-
gate systemic aspects of molecular changes in sex hor-
mone metabolism after menopause [76], as well as direct
and indirect effects of estrogens on cartilage in various
populations [77].
A widely used approach to identify the influence of
menopause on connective tissue homeostasis has been
to examine the influence of surgical menopause (surgical
removal of the ovaries or ovaries + uterus) on connect-
ive tissues of the knee and bones. Results have indicated
that the consequences at the mRNA level in the rabbit
are not the same for all connective tissues of the knee
[78], there is a rapid onset of osteopenia in mice and rats
[79,80], and surgical menopause in primates leads to
osteopenia [48]. However, the decline in systemic estro-
gens in primates did not result in changes in the response
of the patellar tendon or ACL to mechanical load even
after two years, which suggests that postmenopausalreductions in serum estrogens in primates also may not
influence homeostasis of connective tissues of the knee
equally.
One feature of this work, especially the studies of
osteoporosis in human populations, is that the loss of
bone density and structure is variable across individuals.
Although a genetic component is likely involved, loss of
ovarian function after menopause leads to different rates
of bone loss. Because variable loss of bone mass has also
been observed in astronauts during exposure to micro-
gravity [81], the rate of bone loss is likely influenced by
mechanical factors and the balance between anabolism
and catabolism in a tissue [82]. If the findings in bone
translate to other tissues of the knee, this may help ex-
plain the individual variations in the development and
progression of knee OA in females based on the contri-
bution of the sex hormone-hormone receptor set point
(e.g., levels and type of hormone receptor, hormone-
receptor modulating proteins, local metabolism of hor-
mones) in each tissue. Such variation may be relevant to
knee OA because bone changes, particularly subchon-
dral bone, during the development of OA [83,84].
A limitation of the surgical menopause approach is
that it is usually performed on young adult animals and
as such does not account for the superimposed age-
related changes on the knee tissues. For instance, it has
been reported that loss of knee cartilage is much greater
in 50- to 79-year-old women than in age-matched men
[85], which suggests that there are distinct effects of age
and menopause. Therefore, the surgical menopause
models using younger animals do not capture the age-
associated adaptations in the tissues, which limits the in-
terpretation of the findings.
Sex differences in inflammation
OA is an inflammatory disease [86,87] and women tend
to have more robust inflammatory and immune
responses than males [88]. The greater prevalence of
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to development and persistence of inflammatory cyto-
kines in the knee. Such effects may be secondary to the
influence of hormones. For example, postmenopausal
reductions in circulating estrogen are associated with an
increase in the production of inflammatory cytokines,
such as interleukin-6 (IL-6) [89]. The possibility that
hormone-associated changes in systemic and tissue-
specific inflammatory cytokines can influence the risk of
knee OA should be addressed in future studies so that it
is possible to identify those individuals at higher risk.
Conclusion
A major research gap in this area is the lack of relevant
and reproducible cell culture and animal models that
can be used to describe the etiology and progression of
knee OA disease and to understand the underlying
mechanisms and the role of sex hormones. There is little
understanding of how the inflammatory process contri-
butes to knee OA development and progression, and
whether such effects are sex-specific. It is clear that risk
level varies among women, but that women are at higher
risk than males. Sex hormones and hormonal variation
have been implicated in knee OA risk, but much of the
data are correlative and the underlying cellular or mo-
lecular mechanisms are unknown. In parallel with the
recognition of sex-based differential risks, however, a lit-
erature has evolved that provides new clues on how sex
hormones and their receptors can influence connective
tissues. What is missing is the integration of information
on hormone effects on connective tissues and cells with
the augmented risk in females for loss of knee function via
OA, which will be needed to identify sex-specific mechan-
isms and therapeutic targets for prevention and treatment.
GAPS In our knowledge
A number of investigations by many groups have
revealed details on how sex hormones (local and system-
ically produced) and their receptors can influence cells
of connective tissues of the knee complex. However, the
incorporation of this new information into an under-
standing of how the findings contribute to risk for knee
injury and degenerative disease, and the functioning of
the knee in a variety of biomechanical environments
remains elusive. Thus, there is a real gap in translating
the basic biomedical findings to the clinical setting. Of
critical importance is the use of such information in the
prevention of knee injury and further risk for degenera-
tive loss of function. Only through such translation can
risk be mitigated, and development of appropriate inter-
ventions fostered.
It is clear from the literature discussed that consider-
able knowledge has been generated over the past decade
regarding the potential of connective tissues of the kneeto generate and respond to sex hormones that may con-
tribute to the observed sex differences in risk for loss of
knee function and integrity due to injury and degenera-
tive diseases such as OA. However, there remain signifi-
cant gaps in our understanding of how sex steroid
contribute to knee OA (Table 2). Moreover, the use of
this information to establish cause-and-effect relations
between the two sets of observations remains the most
significant gap in our understanding of the cellular and
molecular basis for the risk.
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